Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

NASDAQ:BDSX - Nasdaq - US09075X1081 - Common Stock - Currency: USD

0.2867  -0.01 (-4.4%)

After market: 0.29 +0 (+1.15%)

Fundamental Rating

2

BDSX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative. BDSX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDSX has reported negative net income.
In the past year BDSX has reported a negative cash flow from operations.
BDSX had negative earnings in each of the past 5 years.
In the past 5 years BDSX always reported negative operating cash flow.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BDSX's Return On Assets of -46.87% is on the low side compared to the rest of the industry. BDSX is outperformed by 91.18% of its industry peers.
With a Return On Equity value of -365.44%, BDSX is not doing good in the industry: 80.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -46.87%
ROE -365.44%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

BDSX's Gross Margin of 78.38% is amongst the best of the industry. BDSX outperforms 94.12% of its industry peers.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
BDSX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDSX has more shares outstanding
BDSX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BDSX has a worse debt to assets ratio.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.49, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX's Altman-Z score of -7.49 is on the low side compared to the rest of the industry. BDSX is outperformed by 91.18% of its industry peers.
A Debt/Equity ratio of 3.32 is on the high side and indicates that BDSX has dependencies on debt financing.
BDSX's Debt to Equity ratio of 3.32 is on the low side compared to the rest of the industry. BDSX is outperformed by 78.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.32
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC12.86%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.22 indicates that BDSX has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.22, BDSX is doing good in the industry, outperforming 78.43% of the companies in the same industry.
A Quick Ratio of 2.22 indicates that BDSX has no problem at all paying its short term obligations.
The Quick ratio of BDSX (2.22) is better than 78.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.27% over the past year.
BDSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.77%.
The Revenue has been growing by 23.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)35.77%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%21.19%

3.2 Future

Based on estimates for the next years, BDSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.89% on average per year.
BDSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.19% yearly.
EPS Next Y29.57%
EPS Next 2Y25.21%
EPS Next 3Y19.89%
EPS Next 5YN/A
Revenue Next Year15.95%
Revenue Next 2Y22.46%
Revenue Next 3Y19.19%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

BDSX's earnings are expected to grow with 19.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.21%
EPS Next 3Y19.89%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (6/13/2025, 8:00:01 PM)

After market: 0.29 +0 (+1.15%)

0.2867

-0.01 (-4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners35.83%
Inst Owner Change-9.29%
Ins Owners26.2%
Ins Owner Change7.77%
Market Cap42.02M
Analysts80
Price Target1.84 (541.79%)
Short Float %3.84%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.79%
Min EPS beat(2)-15.34%
Max EPS beat(2)11.77%
EPS beat(4)3
Avg EPS beat(4)4.4%
Min EPS beat(4)-15.34%
Max EPS beat(4)14.75%
EPS beat(8)7
Avg EPS beat(8)7.57%
EPS beat(12)9
Avg EPS beat(12)4.28%
EPS beat(16)11
Avg EPS beat(16)0.46%
Revenue beat(2)1
Avg Revenue beat(2)-4.41%
Min Revenue beat(2)-9.55%
Max Revenue beat(2)0.74%
Revenue beat(4)2
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-2.3%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-3.01%
PT rev (1m)-41.94%
PT rev (3m)-41.94%
EPS NQ rev (1m)-22.02%
EPS NQ rev (3m)-17.81%
EPS NY rev (1m)-17.32%
EPS NY rev (3m)-11.54%
Revenue NQ rev (1m)-18.46%
Revenue NQ rev (3m)-18.4%
Revenue NY rev (1m)-11.75%
Revenue NY rev (3m)-11.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.51
BVpS0.08
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.87%
ROE -365.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.38%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score4
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 3.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.03%
Cap/Sales 4.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -7.49
F-Score4
WACC12.86%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y29.57%
EPS Next 2Y25.21%
EPS Next 3Y19.89%
EPS Next 5YN/A
Revenue 1Y (TTM)35.77%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%21.19%
Revenue Next Year15.95%
Revenue Next 2Y22.46%
Revenue Next 3Y19.19%
Revenue Next 5YN/A
EBIT growth 1Y9.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.86%
EBIT Next 3Y31.94%
EBIT Next 5YN/A
FCF growth 1Y10.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.02%
OCF growth 3YN/A
OCF growth 5YN/A